48,833
edits
Difference between revisions of "Intraductal carcinoma of the prostate"
Jump to navigation
Jump to search
Intraductal carcinoma of the prostate (view source)
Revision as of 14:54, 4 August 2022
, 14:54, 4 August 2022no edit summary
| (13 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
| Caption = Intraductal carcinoma of prostate. [[H&E stain]]. | | Caption = Intraductal carcinoma of prostate. [[H&E stain]]. | ||
| Synonyms = | | Synonyms = | ||
| Micro = '' | | Micro = see ''microscopic'' section | ||
| Subtypes = | | Subtypes = | ||
| LMDDx = invasive [[prostatic carcinoma]], [[high grade prostatic intraepithelial neoplasia]] | | LMDDx = invasive [[prostatic carcinoma]], [[high grade prostatic intraepithelial neoplasia]] | ||
| Line 11: | Line 11: | ||
| IHC = basal cells are present (CK34betaE12 +ve, p63 +ve) | | IHC = basal cells are present (CK34betaE12 +ve, p63 +ve) | ||
| EM = | | EM = | ||
| Molecular = | | Molecular = +/-BRCA2 mutation | ||
| IF = | | IF = | ||
| Gross = | | Gross = | ||
| Line 17: | Line 17: | ||
| Site = [[prostate gland]] | | Site = [[prostate gland]] | ||
| Assdx = | | Assdx = | ||
| Syndromes = | | Syndromes = | ||
| Clinicalhx = | | Clinicalhx = | ||
| Signs = | | Signs = | ||
| Line 27: | Line 27: | ||
| Prognosis = poor, strongly suggestive invasion if not present | | Prognosis = poor, strongly suggestive invasion if not present | ||
| Other = | | Other = | ||
| ClinDDx = | | ClinDDx = | ||
| Tx = | | Tx = | ||
}} | }} | ||
| Line 41: | Line 41: | ||
**For comparison: HGPIN ~70% agreement, invasive carcinoma ~73% agreement. | **For comparison: HGPIN ~70% agreement, invasive carcinoma ~73% agreement. | ||
*Uncommon finding ~ 3% of cases in a series of 1176 prostate biopsies.<ref name=pmid23931616>{{Cite journal | last1 = Watts | first1 = K. | last2 = Li | first2 = J. | last3 = Magi-Galluzzi | first3 = C. | last4 = Zhou | first4 = M. | title = Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. | journal = Histopathology | volume = 63 | issue = 4 | pages = 574-9 | month = Oct | year = 2013 | doi = 10.1111/his.12198 | PMID = 23931616 }}</ref> | *Uncommon finding ~ 3% of cases in a series of 1176 prostate biopsies.<ref name=pmid23931616>{{Cite journal | last1 = Watts | first1 = K. | last2 = Li | first2 = J. | last3 = Magi-Galluzzi | first3 = C. | last4 = Zhou | first4 = M. | title = Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. | journal = Histopathology | volume = 63 | issue = 4 | pages = 574-9 | month = Oct | year = 2013 | doi = 10.1111/his.12198 | PMID = 23931616 }}</ref> | ||
===Prevalence=== | |||
Prevalence varies by risk/stage - based on a systematic review by Porter ''et al.'':<ref name=pmid28342640>{{Cite journal | last1 = Porter | first1 = LH. | last2 = Lawrence | first2 = MG. | last3 = Ilic | first3 = D. | last4 = Clouston | first4 = D. | last5 = Bolton | first5 = DM. | last6 = Frydenberg | first6 = M. | last7 = Murphy | first7 = DG. | last8 = Pezaro | first8 = C. | last9 = Risbridger | first9 = GP. | title = Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. | journal = Eur Urol | volume = 72 | issue = 4 | pages = 492-495 | month = Oct | year = 2017 | doi = 10.1016/j.eururo.2017.03.013 | PMID = 28342640 }}</ref> | |||
{| class="wikitable sortable" | |||
! Group | |||
! Prevalence | |||
|- | |||
| WHO1 † | |||
| 2% | |||
|- | |||
| WHO2 † or WHO3 † | |||
| 23% | |||
|- | |||
| WHO4 † or WHO5 † | |||
| 37% | |||
|- | |||
| Metastasis or biochemical recurrence | |||
| 56% | |||
|} | |||
† WHO1 = WHO [[prostate cancer grading|grade group]] 1 (Gleason score 6), WHO2 = WHO grade group 2 or 3 (Gleason score 7 (3+4 or 4+3), WHO3 = WHO grade group 4 or 5 (Gleason score 8, 9 or 10) | |||
==Microscopic== | ==Microscopic== | ||
| Line 52: | Line 72: | ||
Notes: | Notes: | ||
*† "Dense" is defined as "more solid than luminal areas"; >50% of the lesion area is cells, as opposed to empty space. | |||
*‡ Epstein's paper does not explicitly state that it is the area; however, there is near consensus in an ENUP survey that this is the case.<ref>Varma M, Egevad L, Berney D, Bubendorf L, Compérat EM, Hes O, van Leenders G, Kristiansen G, Intraductal Carcinoma of the Prostate (IDCP) Reporting Practice: A Survey of Practicing Pathologists. United States and Canadian Academy of Pathology Annual Meeting 2018. Available at: [https://www.xcdsystem.com/uscap/program/2018/index.cfm?pgid=1&qfixed=1&SessionType=Platform%20Presentation https://www.xcdsystem.com/uscap/program/2018/index.cfm?pgid=1&qfixed=1&SessionType=Platform%20Presentation].</ref> The equivalent diameter multiplier is ''sqrt(6)'' ~ 2.45; 6x area ~= 2.45x diameter. | *‡ Epstein's paper does not explicitly state that it is the area; however, there is near consensus in an ENUP survey that this is the case.<ref>Varma M, Egevad L, Berney D, Bubendorf L, Compérat EM, Hes O, van Leenders G, Kristiansen G, Intraductal Carcinoma of the Prostate (IDCP) Reporting Practice: A Survey of Practicing Pathologists. United States and Canadian Academy of Pathology Annual Meeting 2018. Available at: [https://www.xcdsystem.com/uscap/program/2018/index.cfm?pgid=1&qfixed=1&SessionType=Platform%20Presentation https://www.xcdsystem.com/uscap/program/2018/index.cfm?pgid=1&qfixed=1&SessionType=Platform%20Presentation].</ref> The equivalent diameter multiplier is ''sqrt(6)'' ~ 2.45; 6x area ~= 2.45x diameter. | ||
| Line 98: | Line 119: | ||
==IHC== | ==IHC== | ||
Features - basal cells present: | Features - basal cells present: | ||
*CK34betaE12 +ve. | *[[CK34betaE12]] +ve. | ||
*p63 +ve. | *[[p63]] +ve. | ||
==Molecular== | |||
*+/-[[BRCA2 mutation]].<ref name=pmid28067867>{{cite journal |authors=Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG |title=Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories |journal=Nat Commun |volume=8 |issue= |pages=13671 |date=January 2017 |pmid=28067867 |pmc=5227331 |doi=10.1038/ncomms13671 |url=}}</ref> | |||
Note: | |||
*BRCA1 associated prostate cancer seems to be less common/less studied.<ref name=pmid29433453>{{cite journal |authors=Ibrahim M, Yadav S, Ogunleye F, Zakalik D |title=Male BRCA mutation carriers: clinical characteristics and cancer spectrum |journal=BMC Cancer |volume=18 |issue=1 |pages=179 |date=February 2018 |pmid=29433453 |pmc=5809938 |doi=10.1186/s12885-018-4098-y |url=https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4098-y }}</ref> | |||
==See also== | ==See also== | ||
| Line 105: | Line 132: | ||
*[[Prostate carcinoma]]. | *[[Prostate carcinoma]]. | ||
*[[Ductal adenocarcinoma of the prostate]]. | *[[Ductal adenocarcinoma of the prostate]]. | ||
*[[Cribriform pattern within invasive prostate carcinoma]]. | |||
==References== | ==References== | ||